Cardiovascular Systems, Inc. (CSII)
| Market Cap | 1.66B |
| Revenue (ttm) | 228.43M |
| Net Income (ttm) | -20.19M |
| Shares Out | 38.81M |
| EPS (ttm) | -0.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 2 |
| Last Price | $41.38 |
| Previous Close | $41.90 |
| Change ($) | -0.52 |
| Change (%) | -1.24% |
| Day's Open | 41.72 |
| Day's Range | 40.95 - 42.09 |
| Day's Volume | 131,731 |
| 52-Week Range | 26.00 - 48.28 |
ST. PAUL, Minn.--(BUSINESS WIRE)--CSII Q3 Conferences
Cardiovascular System's (CSII) Diamondback 360 Coronary OAS provides physicians in Europe with an effective treatment option for difficult-to-treat patient population.
ST. PAUL, Minn.--(BUSINESS WIRE)--First patient treated in Europe
Cardiovascular Systems (CSII) registers dismal revenues despite gradual recovery in business amid the pandemic.
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 100.00% and -1.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead fo...
Shares of Cardiovascular Systems (NASDAQ:CSII) were unchanged in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 100.00% year over ye...
ST. PAUL, Minn.--(BUSINESS WIRE)--CSI Q2 Financial Results
ST. PAUL, Minn.--(BUSINESS WIRE)--CSI Q2 Financial Results
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES PARTNERSHIP WITH CHANSU VASCULAR TECHOLOGIES, LLC TO DEVELOP NEW DRUG-COATED BALLOON TECHNOLOGY
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES SACHIN H. JAIN, MD, MBA, JOINS BOARD OF DIRECTORS
Cardiovascular Systems (CSII) aims to expand treatment options in Europe for patients suffering from severely calcified coronary artery disease following the receipt of regulatory clearance.
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. RECEIVES CE MARK FOR DIAMONDBACK 360® CORONARY ORBITAL ATHERECTOMY SYSTEM
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO WEBCAST FISCAL 2021 SECOND-QUARTER EARNINGS CONFERENCE CALL WEDNESDAY, FEBRUARY 3
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO PRESENT AT THE 23RD ANNUAL NEEDHAM VIRTUAL GROWTH CONFERENCE
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO PRESENT AT THE STIFEL 2020 VIRTUAL HEALTHCARE CONFERENCE
Cardiovascular Systems (CSII) registers dismal segmental revenues despite gradual recovery in business amid the pandemic.
Cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q1 2021 Results - Earnings Call Transcript
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 78.26% and 7.59%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for...
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2021 FIRST-QUARTER FINANCIAL RESULTS
Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2021 first-quarter conference call on Wednesday, November 4, 2020, a...
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for pa...
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for pa...
Cardiovascular Systems' (CSII) encouraging REACH PVI study outcome and launch of a physician finder are positives.
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC.
Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q4 earnings as patients avoid hospitals.
Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q2 earnings as patients avoid hospitals.
Cardiovascular Systems' (CSII) CEO Scott Ward on Q4 2020 Results - Earnings Call Transcript
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 2.27% and 10.49%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the ...
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC.
Cardiovascular Systems (NASDAQ: CSII) releases its next round of earnings this Tuesday, August 04.
Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS PRESENTS REACH PVI STUDY AT THE NEW CARDIOVASCULAR HORIZONS CONFERENCE
The market is reacting to the company's decision to initiate a public offering of common stock.
Cardiovascular Systems (CSII) witnesses a significant decline in procedure volumes in Q3 for patients treated with orbital atherectomy devices.
Cardiovascular Systems' (CSII) CEO Scott Ward on Q3 2020 Results - Earnings Call Transcript
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 11.11% and -4.42%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for th...
Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?
Cardiovascular Systems (CSII) continues to register solid top-line growth on strength in the domestic atherectomy businesses.
Figuring out bloated toxic stocks on a consistent basis and discarding them at the right time is the key to successful investing.
We are upbeat about Cardiovascular Systems' (CSII) year-over-year uptick in global Coronary and peripheral device revenues during Q2.
Cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q2 2020 Results - Earnings Call Transcript
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -233.33% and 0.65%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead fo...
Cardiovascular Systems (CSII) is optimistic about maintaining its growth momentum on several recent developments.
This is a major achievement for Cardiovascular Systems (CSII) toward strengthening its portfolio for the treatment of CLI.
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?
We are upbeat about the year-over-year uptick in both Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.
About CSII
Cardiovascular Systems, a medical device company, develops and commercializes various devices to treat peripheral and coronary artery diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary o... [Read more...]
| Industry Medical Devices | IPO Date Feb 26, 2009 |
| CEO Scott Ward | Employees 779 |
| Stock Exchange NASDAQ | Ticker Symbol CSII |
Financial Performance
In 2020, CSII's revenue was $236.55 million, a decrease of -4.63% compared to the previous year's $248.02 million. Losses were -$27.24 million, 10,580.8% more than in 2019.
Analyst Forecasts
According to 10 analysts, the average rating for CSII stock is "Buy." The 12-month stock price forecast is 47.00, which is an increase of 13.58% from the latest price.